Merck(US:MRK)2025-10-30 10:40Financial Performance - Total sales for Q3 2025 reached $17,276 million, a 4% increase compared to Q3 2024[2] - Net income attributable to Merck for Q3 2025 was $5,785 million, reflecting an 83% increase year-over-year[2] - The earnings per share for Q3 2025 was $2.32, an increase of 87% from $1.24 in Q3 2024[2] - The income before taxes for Q3 2025 was $6,745 million, a 65% increase compared to $4,090 million in Q3 2024[2] - The tax rate for Q3 2025 was 14.2%, compared to 22.7% in Q3 2024[2] - The company reported a significant increase in net income for the year-to-date period, totaling $15,301 million, a 14% increase from $13,389 million in the same period last year[2] Sales Performance - Year-to-date sales for 2025 reached $48,611 million, showing no change from the same period in 2024[2] - Total sales for Q3 2025 reached $17,276 million, a 4% increase from $16,657 million in Q3 2024[10] - Pharmaceutical sales were $15,611 million, up 4% from $14,943 million in the same quarter last year[10] - Total sales for September YTD 2025 reached $48,611 million, a slight increase from $48,544 million in 2024[19] - Pharmaceutical sales were $43,299 million in September YTD 2025, remaining relatively stable compared to $43,358 million in 2024[19] Product Sales - Keytruda sales increased by 10% to $8,142 million compared to $7,429 million in Q3 2024[10] - Alliance revenue from Lynparza rose by 12% to $379 million, while Lenvima's revenue increased by 3% to $258 million[10] - Total vaccines sales decreased to $3,370 million from $3,675 million, a decline of 8% year-over-year[14] - Diabetes sales grew to $703 million, up from $592 million, reflecting a 19% increase[16] - Animal health segment reported sales of $1,615 million, a 9% increase from $1,487 million in the previous year[10] - Livestock sales increased by 16% to $1,023 million, while companion animal sales slightly decreased by 2% to $592 million[10] - Keytruda sales increased by 8% to $23,303 million in September YTD 2025, up from $21,646 million in 2024[19] - Gardasil/Gardasil 9 sales decreased significantly by 40% to $4,202 million in September YTD 2025, down from $7,032 million in 2024[19] - Total vaccines sales were $8,347 million in September YTD 2025, down from $10,755 million in 2024, reflecting a decline of 22.4%[23] - Total diabetes sales increased by 11.2% to $2,283 million in September YTD 2025, compared to $2,053 million in 2024[25] - Alliance revenue for Koselugo was $301 million in September YTD 2025, significantly higher than $114 million in 2024[25] Market Performance - The U.S. market contributed $27,371 million to total sales in September YTD 2025, a 14% increase from $24,089 million in 2024[19] - International sales decreased by 13% to $21,240 million in September YTD 2025, down from $24,455 million in 2024[19] - U.S. pharmaceutical sales increased by 15% year-over-year to $9.493 billion in Q3 2025, up from $8.227 billion in Q3 2024[28] - Japan's pharmaceutical sales decreased by 25% year-over-year to $693 million in Q3 2025, down from $919 million in Q3 2024[28] - Sales in China dropped significantly by 62% year-over-year to $377 million in Q3 2025, compared to $996 million in Q3 2024[28] Expenses and Income - Research and development expenses decreased by 28% in Q3 2025, totaling $4,234 million compared to $5,862 million in Q3 2024[2] - The cost of sales for Q3 2025 was $3,855 million, a decrease of 6% from $4,080 million in Q3 2024[2] - Selling, general and administrative expenses for Q3 2025 were $2,633 million, down 4% from $2,731 million in Q3 2024[2] - Interest income for Q3 2025 was $(96) million, compared to $(127) million in Q3 2024[31] - Total net other income/expense for Q3 2025 was $(238) million, an increase in loss compared to $(162) million in Q3 2024[31] - The company reported a total interest expense of $327 million in Q3 2025, slightly down from $330 million in Q3 2024[31] - Exchange losses increased to $56 million in Q3 2025 from $33 million in Q3 2024[31] Future Outlook - The company anticipates continued growth in key therapeutic areas and plans to expand its market presence through new product launches and strategic partnerships[10] - The full-year pharmaceutical sales guidance for 2025 is projected at $57.400 billion, reflecting a slight increase from $57.000 billion in 2024[28]